Document Detail


Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
MedLine Citation:
PMID:  19461031     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: The relative contributions of on-treatment low- and high-density lipoprotein cholesterol (LDL-C, HDL-C), triglycerides, and blood pressure (BP) control on the risk of recurrent stroke or major cardiovascular events in patients with stroke is not well defined. METHODS: We randomized 4731 patients with recent stroke or transient ischemic attack and no known coronary heart disease to atorvastatin 80 mg per day or placebo. RESULTS: After 4.9 years, at each level of LDL-C reduction, subjects with HDL-C value above the median or systolic BP below the median had greater reductions in stroke and major cardiovascular events and those with a reduction in triglycerides above the median or diastolic BP below the median showed similar trends. There were no statistical interactions between on-treatment LDL-C, HDL-C, triglycerides, and BP values. In a further exploratory analysis, optimal control was defined as LDL-C <70 mg per deciliter, HDL-C >50 mg per deciliter, triglycerides <150 mg per deciliter, and SBP/DBP <120/80 mm Hg. The risk of stroke decreased with as the level of control increased (hazard ratio [95% confidence interval] 0.98 [0.76 to 1.27], 0.78 [0.61 to 0.99], 0.62 [0.46 to 0.84], and 0.35 [0.13 to 0.96]) for those achieving optimal control of 1, 2, 3, or 4 factors as compared to none, respectively. Results were similar for major cardiovascular events. CONCLUSIONS: We found a cumulative effect of achieving optimal levels of LDL-C, HDL-C, triglycerides, and BP on the risk of recurrent stroke and major cardiovascular events. The protective effect of having a higher HDL-C was maintained at low levels of LDL-C.
Authors:
Pierre Amarenco; Larry B Goldstein; Michael Messig; Blair J O'Neill; Alfred Callahan; Henrik Sillesen; Michael G Hennerici; Justin A Zivin; K M A Welch;
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2009-05-21
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  40     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-30     Completed Date:  2009-07-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2486-92     Citation Subset:  IM    
Affiliation:
INSERM U-698, Denis Diderot University-Paris VII, Department of Neurology, Bichat University Hospital, Paris, France. pierre.amarenco@bch.aphp.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Anticholesteremic Agents / therapeutic use*
Blood Pressure / physiology*
Cholesterol / blood*
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Female
Heptanoic Acids / therapeutic use*
Humans
Hypercholesterolemia / blood,  drug therapy*,  physiopathology
Ischemic Attack, Transient / epidemiology,  pathology,  prevention & control
Male
Middle Aged
Pyrroles / therapeutic use*
Recurrence / prevention & control
Risk Factors
Stroke / epidemiology,  physiopathology,  prevention & control*
Treatment Outcome
Triglycerides / blood
Young Adult
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Pyrroles; 0/Triglycerides; 110862-48-1/atorvastatin; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of weekend hospital admission on short-term mortality after intracerebral hemorrhage.
Next Document:  CT angiography for intracerebral hemorrhage does not increase risk of acute nephropathy.